Clinical Trial Update: Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DV890 for efficacy and safety in patients with COVID-19 pneumonia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• DV890

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COVID-19 Pneumonia, Impaired Respiratory Function | Phase 2 | Status: COMPLETED | Results posted: 2021-11-30